Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 1, 2007, Pages 1-8

  Shimizu, Chikako ^a   Ando, Masashi ^a   Kouno, Tsutomu ^a   Katsumata, Noriyuki ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Advantage; Breast cancer; Long term outcome; Pre operative chemotherapy; Prediction; Response

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PLACEBO; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION PROFILING; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE TREATMENT; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICAL ONCOLOGY;

EID: 34447635101     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl122     Document Type: Review

References (93)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: And overview of the randomized trials. Lancet 2005;365:1687-717.
2. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006;12(Suppl 1):S70-S80.
3. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advainced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9.
4. Schick P, Goodstein J, Moor J, Butler J, Senter KL. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983;22:278-82.
5. Sorace RA, Bagley CS, Lichter AS, Danforth DN Jr, Wesley MW, Young RC, et al. The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. World J Surg 1985; 9:775-85.
6. Wolmark N, Wang J, Mamonous E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer. Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
7. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-3865.
8. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-92.
9. Straus MJ, Sege V, Choi SC. The effect of surgery and pretreatment or post-treatment adjuvant chemotherapy on primary tumor growth in an animal model. J Surg Oncol 1975;7:497-512.
10. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
11. Van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224-37.
12. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cacer: A meta-analysis. J Natl Cancer Inst 2005;97:188-97.
13. Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer 1991;63:561-6.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
15. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004;100:2512-32.
16. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel of the use of primary (preoperative) systemic treatment on operable breast cancer: Review and recommendations. J Clin Oncol 2003;21:2600-8.
17. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubine-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294-2302.
18. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicine and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
19. Trudeau M, Sinclair SE, Clemons M, Breast Cancer Disease Site Group. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: A systematic review. Cancer Treat Rev 2005;31:283-302.
20. Estevez LG, Gradishar WJ. Evidence-based use of neaodjuvant taxane in operable and inoperable cancer. Clin Cancer Res 2004;10:3249-61.
21. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
22. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Paik S, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006 (e-published ahead of print on 10 April 2006).
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;344:783.
24. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch AD, Unch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med 2005;353:1629-72.
26. Joensuu H, Kellolumpu-Lehtinen K, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
27. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin and cyclophosphamide for HER2 overexpression Stage II or III breast cancer: A pilot study. J Clin Oncol 2001;21:46-53.
28. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermalgrowth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:2019-27.
29. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: Initial results of a randomized trial in operable breast cancer with HER/2 positive disease. J Clin Oncol 2005;23:3676-85.
30. Yeh E, Slanetz P, Kopans DB, Georgian-Smith D, Moy L, Halpern E, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 2005;184:868-77.
31. Balu-Maestro C, Chappellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002;72:145-52.
32. Moyses B, Haegele P, Rodier JF, Lehmann S, Petet T, Velten M, et al. Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin Breast Cancer 2002;2:304-310.
33. Akashi-Tanaka S, Fukutomi T, Watanabe T. Katsumata N, Nanasawa T, Matsuo K, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 2001; 20:66-73.
34. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-88.
35. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;20:1689-1395.
36. 18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7.
37. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomised comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.
38. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702.
39. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000;89:2187-94.
40. Fernandez A, Cortes M, Benito E, Azpeitia D, Prieto L, Moreno A, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001;22:361-366.
41. Jones JL, Zabicke K, Christian RL, Gadd MA, Hughes KS, Lesnikoski BA, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: Timing is important. Am J Surg 2005;190:517-520.
42. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 1996;16:3105-10.
43. Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000;20:4373-7.
44. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 2005;446:489-96.
45. Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubaky P, et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 2003; 82:207-13.
46. Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005;23:3331-42.
47. Kuerer HM, Newman LA, Buzdar AU, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
48. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
49. Chevallier R, Roche H, Olivier JP, Chollet P, Hurteloup P. Pilot study of intensive chemotherapy 8FEC-HD) results in high histologic response rate. Am J Clin Oncol 1993;16:223-8.
50. Sataloff DM, Manson BA, Prestipino AJ, Seiniqe UL, Leiber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1998;180:297-306.
51. Hankoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekeman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
52. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Significance and survival. Breast 2003;12:320-7.
53. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M, Tsuda H. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001;8:1-2.
54. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006;94:358-62.
55. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004;100:1365-73.
56. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Sur Oncol 2000;7:435-40.
57. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradiction of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23:9304-11.
58. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998;16:107-14.
59. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouziere R, et al. Factors predictive of distant metastasis in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005;23:7098-104.
60. Schneeweiss A, Katretchko J, Sinn HP, Unnebrink K, Rudlowski C, Geberth M, et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs 2004;15:127-35.
61. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Olliala DW, et al. American Joint Committee on Cancer Tumor-Node-Metastasis Stage after meoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005;97:1137-42.
62. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23:8331-9.
63. Vagras-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer treated with induction chemotherapy. Int J Cancer 1999;84:129-34.
64. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005;104:676-81.
65. Bonnefoi H, Diebod-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, et al. Locally advanced/inflammatory breast cancer treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in primary tumour that predic for 5-year clinical outcome? Ann Oncol 2003;14:406-13.
66. Chevillard S, Lebeaeu J, Poulliart P, de Toma C, Beldjord C, Asselain B, et al. Biological and clinical significance of concurrent p53-gene alterations, MDR1-gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 1997;3:2471-8.
67. Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, et al. Changes of topoisomerase II-alpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 2006;12:1501-6.
68. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18:87-93.
69. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, van Praagh I, et al. Scarff-Bloom-Richardson (SBR) grading: A pleitropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791-6.
70. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Loscielny S, Travagli JP, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004;40:342-51.
71. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 2006;17:1228-33.
72. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-8.
73. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Sheelfhout VR, Silva OE, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal carcinoma. Eur J Surg Oncol 2003;29:361-7.
74. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
75. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
76. Schneeweiss A, Katretchko J, Sinn HP, Unnebrink K, Rudlowski C, Geberth M, et al. Only grading has independent impact on breast cancer survival after adjustment for pathologic response to preoperative chemotherapy. Anticancer Drugs 2004;15:127-35.
77. Bottini A, Burruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzgno G, et al. P53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-8.
78. Van Slooten HJ, Clahsen PC, van Dierendonck C, Duval V, Pallud C, Mandard AM, et al. Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996;74:78-85.
79. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1997;74:957-67.
80. Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassoe AM, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
81. Kandioler-Exkersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
82. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
83. Ayers M, Symmans WF, Stec J, Demokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22;2284-93.
84. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:69-77.
85. Fulgueira MA, Carraro DM, Bretani H, Patrao DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-43.
86. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
87. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnositic and prognositic classification. J Natl Cancer Inst 2003;95:14-8.
88. Ellis M, Ballma K. Trawling for genes that predict response to breast cancer adjuvant therapy. J Clin Oncol 2004;22:2267-9.
89. Reid JF, Lusa L, De Cecco L, Coradini D, Veronesi S, Daidone MG, et al. Limits of predictive models using microarray data for breast cancer clinical outcome. J Natl Cancer Inst 2005;97:927-30.
90. Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor of antiestrogen? Br J Cancer 2004;90:20-5.
91. Mohshin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23:2460-8.
92. Polychronis A, Sinnett HD, Hadijiminas D, Singhal H, Mansi JL, Shivapatham D, et al. Preoperative gefinitib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor positive primary breast cancer: A double-blind placebo-controlled phase II randomized trial. Lancet Oncol 2005;6:383-91.
93. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001;98;10969-10874.